A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Recruiting · NCT07336472 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT07336472 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fortvita Biologics (USA)Inc. | 7 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope - Duarte | Duarte | United States | 7 |
| City of Hope - Lennar | Irvine | United States | 4 |
| Emory | Atlanta | United States | 9 |
| Honor Health | Scottsdale | United States | 27 |
| MD Anderson | Houston | United States | 56 |
| Memorial Sloan Kettering | New York | United States | 5 |